<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01340885</url>
  </required_header>
  <id_info>
    <org_study_id>PANUC - Lou</org_study_id>
    <secondary_id>5P50NS062684-02</secondary_id>
    <nct_id>NCT01340885</nct_id>
  </id_info>
  <brief_title>Cognitive Decline in Non-demented PD</brief_title>
  <official_title>Cognitive Dysfunction in PD: Pathophysiology and Potential Treatments, a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the relationship between attention and quality of
      life and how rivastigmine and atomoxetine alter attention in non-demented persons with
      Parkinson's disease (PD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cognitive dysfunction can occur in early stage of Parkinson's disease (PD) and increases as
      PD progresses. Attention deficits in PD patients with dementia strongly predict the
      impairment of their daily living activities.

      Previous studies have shown that atomoxetine improves PD executive dysfunction and
      rivastigmine improves attention deficits in PD patients with dementia without worsening the
      motor symptoms.

      The aim of this study is to examine the effect of atomoxetine and rivastigmine on attention
      and quality of life in PD patients without disabling cognitive impairment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">January 2013</completion_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Attention network effects</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>6 weeks</time_frame>
    <description>PDQ-39</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroop Color Word Test</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daytime sleepiness</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>atomoxetine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Strattera 10-30 mg b.i.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rivastigimine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Exelon 1.5-4.5 mg b.i.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>sugar pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Strattera</intervention_name>
    <description>10-30 mg b.i.d. for 6 weeks</description>
    <arm_group_label>atomoxetine</arm_group_label>
    <other_name>atomoxetine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exelon</intervention_name>
    <description>1.5-4.5 mg b.i.d. for 6 weeks</description>
    <arm_group_label>rivastigimine</arm_group_label>
    <other_name>rivastigmine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2-6 pills for 6 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Parkinson's disease

          -  Respond to levodopa therapy

        Exclusion Criteria:

          -  Dementia

          -  Psychiatric disorders including anxiety disorders, dissociative disorders, mood
             disorders, schizophrenia and related disorders, or ADD/ADHD

          -  Any clinically unstable disease such as cancer, HIV/AIDS, heart condition, liver
             disease, kidney or renal failure or others that might require hospitalization

          -  Evidence for another neurological disease (history of seizures, Alzheimer disease,
             multiple sclerosis or other movement disorders);

          -  Currently using any of the study drugs;

          -  Colorblindness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jau-Shin Lou, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diana Dimitrova, PhD</last_name>
    <phone>503-494-7269</phone>
    <email>dimitrov@ohsu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2011</study_first_submitted>
  <study_first_submitted_qc>April 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2011</study_first_posted>
  <last_update_submitted>November 9, 2012</last_update_submitted>
  <last_update_submitted_qc>November 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Jau-Shin Lou</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>attention</keyword>
  <keyword>mild cognitive impairment</keyword>
  <keyword>dementia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atomoxetine Hydrochloride</mesh_term>
    <mesh_term>Rivastigmine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

